CMS published details of its proposed 2027 outpatient payment rule that would pair a base rate increase with steep cuts tied to 340B drug payments and changes expanding site-neutral payment approaches for certain services. Provider groups warned that the combined changes could push hospital payments into negative territory. The rule proposal is a near-term catalyst for hospital budgeting because outpatient reimbursement affects how quickly new oncology products can be adopted in real-world clinical workflows, particularly where 340B-aligned purchasing and administration models are central. For biotech manufacturers, the policy shift adds another variable to reimbursement forecasting and reinforces the need for tighter scenario planning around site-of-care and drug procurement economics.